Novo’s CEO Turns to Next Targets After Losing Metsera to Pfizer - Bloomberg.com

Novo Nordisk A/S Chief Executive Officer Mike Doustdar may have lost out to Pfizer Inc. in a $10 billion takeover battle for obesity drug developer Metsera Inc. But don’t expect him to give up on dealmaking any time soon as the Danish company seeks to regain …

You will be redirected in 10 seconds.